Skip to contentK
Keros Therapeutics, Inc.
K
KROSKeros Therapeutics, Inc. Q2 2026 · 10-Q
Revenue$0.00$0.00−100.0% vs Q2 2025 Net Income-$28.71M-$28.71MN/M vs Q2 2025 EPS Diluted-$1.45-$1.45N/M vs Q2 2025 Operating Income-$30,937,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Keros Therapeutics, Inc. · CIK 1664710 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$20,576,000N/M ended Jun 30, 2026 · filed Aug 3, 2026 · 34 d after period end